Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $115.00 short call and a strike $125.00 long call offers a potential 14.42% return on risk over the next 32 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $115.00 by expiration. The full premium credit of $1.26 would be kept by the premium seller. The risk of $8.74 would be incurred if the stock rose above the $125.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 29.8 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Drugmakers urge FDA security audit after cyber breach
Wed, 18 Dec 2013 01:27:22 GMT
9:15 am Amgen announces positive top-line results from Phase 3 MENDEL-2 trial of evolocumab in patients with high cholesterol; trial with evolocumab met its co-primary endpoints
Tue, 17 Dec 2013 23:04:43 GMT
Briefing.com – 9:15 am Amgen announces positive top-line results from Phase 3 MENDEL-2 trial of evolocumab in patients with high cholesterol; trial with evolocumab met its co-primary endpoints
The Race To Treat Stage III Melanoma Just Got A Lot More Interesting
Tue, 17 Dec 2013 18:46:07 GMT
Seeking Alpha – (Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.) In a November article, entitled “Treating Melanoma: Only The Best Shall Survive”, …
Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
Tue, 17 Dec 2013 15:40:05 GMT
noodls – THOUSAND OAKS, Calif., Dec. 17, 2013 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Phase 3 MENDEL-2 (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not …
Amgen announces MENDEL-2 Phase 3 trial met co-primary endpoints
Tue, 17 Dec 2013 14:19:05 GMT
theflyonthewall.com – Amgen announced that the Phase 3 MENDEL-2 trial with evolocumab met its co-primary endpoints, which was the percent reduction from baseline in low-density lipoprotein cholesterol at week 12 and the mean …
Related Posts
Also on Market Tamer…
Follow Us on Facebook